Viridian Therapeutics (VRDN) to Announce Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) is projected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Viridian Therapeutics to post earnings of ($1.02) per share and revenue of $0.0310 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The firm’s quarterly revenue was up 95.8% compared to the same quarter last year. During the same period last year, the company posted ($0.87) earnings per share. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viridian Therapeutics Stock Up 2.1%

Shares of NASDAQ VRDN opened at $19.31 on Tuesday. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The firm’s 50-day simple moving average is $18.01 and its 200 day simple moving average is $21.91. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -5.82 and a beta of 0.91.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the transaction, the director owned 5,090,928 shares of the company’s stock, valued at $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Commodore Capital LP raised its holdings in shares of Viridian Therapeutics by 35.4% in the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares during the period. State Street Corp grew its holdings in Viridian Therapeutics by 35.7% during the fourth quarter. State Street Corp now owns 3,466,560 shares of the company’s stock worth $107,879,000 after purchasing an additional 912,394 shares during the period. Price T Rowe Associates Inc. MD increased its position in Viridian Therapeutics by 42.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock worth $107,036,000 after buying an additional 1,021,310 shares during the last quarter. Geode Capital Management LLC increased its position in Viridian Therapeutics by 12.8% during the fourth quarter. Geode Capital Management LLC now owns 1,992,174 shares of the company’s stock worth $62,007,000 after buying an additional 225,987 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in Viridian Therapeutics by 75.6% in the fourth quarter. Wellington Management Group LLP now owns 1,971,411 shares of the company’s stock valued at $61,350,000 after buying an additional 848,879 shares during the period.

Wall Street Analyst Weigh In

VRDN has been the subject of a number of research reports. Wedbush raised their price target on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Weiss Ratings cut Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Stifel Nicolaus set a $39.00 target price on Viridian Therapeutics in a research note on Wednesday, May 13th. Wells Fargo & Company raised Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $20.00 to $31.00 in a research note on Monday, June 29th. Finally, Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.79.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.